Advocates push for PBS subsidy of weight-loss drugs for PMOS
The POSAA urges government funding for GLP-1 weight-loss drugs on the PBS for Australian women with PMOS.
Some women living with PMOS are pushing for taxpayer-funded access to GLP-1 weight-loss drugs. The condition causes irregular periods, excess hair growth, weight gain and hair thinning, and raises the risk of type 2 diabetes, heart disease and endometrial cancer.
Doctors currently prescribe GLP-1s off-label for PMOS because they are not officially approved by the TGA for this use. The cost is steep: patients pay several hundred dollars each month out of pocket.
Half a million Australians are already using weight-loss medications regularly. Experts say the evidence is still emerging on how well GLP-1s work for PMOS.
Long-term use remains expensive.
- One in eight
- Women with PMOS in Australia
- Several hundred dollars
- Monthly out-of-pocket cost
- Half a million
- Australians using weight-loss
- Lorna Berry
- POSAA spokesperson
Why it mattersMany women with PMOS cannot afford treatments that show emerging promise.
AustraliaOne in eight Australian women have PMOS; those without money for private weight-loss drugs may miss a treatment option currently being debated for federal subsidy.
✓ Claims checked against the source and corrected before publish. checked 3 h ago
Open this story in InSnip →
